-DOCSTART- -X- O
Modified -X- _ O
Vaccinia -X- _ O
virus -X- _ O
Ankara -X- _ O
( -X- _ O
MVA -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
promising -X- _ O
vaccine -X- _ O
vector -X- _ O
with -X- _ O
an -X- _ O
excellent -X- _ O
safety -X- _ O
profile. -X- _ O
However -X- _ O
, -X- _ O
despite -X- _ O
extensive -X- _ O
pre-clinical -X- _ O
and -X- _ O
clinical -X- _ O
testing -X- _ O
, -X- _ O
surprisingly -X- _ O
little -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
the -X- _ O
cellular -X- _ O
tropism -X- _ O
of -X- _ O
MVA -X- _ O
, -X- _ O
especially -X- _ O
in -X- _ O
relevant -X- _ O
animal -X- _ O
species. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
performed -X- _ O
in -X- _ B-Outcome
vitro -X- _ I-Outcome
, -X- _ I-Outcome
ex -X- _ I-Outcome
vivo -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
experiments -X- _ I-Outcome
with -X- _ O
recombinant -X- _ B-Intervention
MVA -X- _ I-Intervention
expressing -X- _ I-Intervention
green -X- _ I-Intervention
fluorescent -X- _ I-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
rMVA-GFP -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
In -X- _ O
both -X- _ O
human -X- _ B-Patient
peripheral -X- _ I-Patient
blood -X- _ I-Patient
mononuclear -X- _ I-Patient
cells -X- _ I-Patient
and -X- _ O
mouse -X- _ B-Patient
lung -X- _ I-Patient
explants -X- _ I-Patient
, -X- _ O
rMVA-GFP -X- _ O
predominantly -X- _ O
infected -X- _ O
antigen -X- _ O
presenting -X- _ O
cells. -X- _ O
Subsequent -X- _ O
in -X- _ O
vivo -X- _ O
experiments -X- _ O
performed -X- _ O
in -X- _ O
mice -X- _ B-Patient
, -X- _ O
ferrets -X- _ B-Patient
and -X- _ O
non-human -X- _ B-Patient
primates -X- _ I-Patient
indicated -X- _ O
that -X- _ O
preferential -X- _ B-Outcome
targeting -X- _ I-Outcome
of -X- _ I-Outcome
dendritic -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
alveolar -X- _ I-Outcome
macrophages -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
after -X- _ I-Outcome
respiratory -X- _ I-Outcome
administration -X- _ I-Outcome
, -X- _ O
although -X- _ O
subtle -X- _ O
differences -X- _ O
were -X- _ O
observed -X- _ O
between -X- _ O
the -X- _ O
respective -X- _ O
animal -X- _ O
species. -X- _ O
Following -X- _ O
intramuscular -X- _ B-Outcome
injection -X- _ I-Outcome
, -X- _ O
rMVA-GFP -X- _ O
was -X- _ O
detected -X- _ O
in -X- _ O
interdigitating -X- _ B-Outcome
cells -X- _ I-Outcome
between -X- _ I-Outcome
myocytes -X- _ I-Outcome
, -X- _ O
but -X- _ O
also -X- _ O
in -X- _ O
myocytes -X- _ B-Outcome
themselves. -X- _ I-Outcome
These -X- _ O
data -X- _ O
are -X- _ O
important -X- _ O
in -X- _ O
advancing -X- _ O
our -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
basis -X- _ O
for -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
MVA-based -X- _ O
vaccines -X- _ O
and -X- _ O
aid -X- _ O
rational -X- _ O
vaccine -X- _ O
design -X- _ O
and -X- _ O
delivery -X- _ O
strategies -X- _ O
. -X- _ O

